Cargando…

Case report: Successful treatment with the combined therapy of interferon-alpha 2b and anlotinib in a patient with advanced hepatic epithelioid hemangioendothelioma

Hepatic epithelioid hemangioendothelioma (HEH) is a very rare tumor originating from vascular endothelial cells, with unpredictable malignancy. At present, there is no standard treatment protocol yet established. Both surgical resection and liver transplantation have been reported to be effective tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiaolei, Zhou, Ruiquan, Si, Shuang, Liu, Liguo, Yang, Shiwei, Han, Dongdong, Tan, Haidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755491/
https://www.ncbi.nlm.nih.gov/pubmed/36530920
http://dx.doi.org/10.3389/fmed.2022.1022017
_version_ 1784851431907393536
author Liu, Xiaolei
Zhou, Ruiquan
Si, Shuang
Liu, Liguo
Yang, Shiwei
Han, Dongdong
Tan, Haidong
author_facet Liu, Xiaolei
Zhou, Ruiquan
Si, Shuang
Liu, Liguo
Yang, Shiwei
Han, Dongdong
Tan, Haidong
author_sort Liu, Xiaolei
collection PubMed
description Hepatic epithelioid hemangioendothelioma (HEH) is a very rare tumor originating from vascular endothelial cells, with unpredictable malignancy. At present, there is no standard treatment protocol yet established. Both surgical resection and liver transplantation have been reported to be effective treatments for HEH; however, multiple intrahepatic lesions or extrahepatic metastasis make these procedures unsuitable to most patients. Systematic therapy has also been investigated, but the results are undetermined due to the limited cases. Interferon-alpha 2b (IFN-a 2b) has also been used for the treatment of HEH. Based on our previous study, the rate of tumor regression with IFN-a 2b monotherapy was more than 50%. Here, we reported a patient with advanced HEH, who achieved a partial response with the combined therapy of anlotinib and IFN-a 2b. The tumor stayed stable for 2 years with anlotinib monotherapy and regressed 3 months after the combined therapy of anlotinib and IFN-a 2b. The synergistic effect of combined therapy with anlotinib and IFN-a 2b provided promising guidance for future clinical study.
format Online
Article
Text
id pubmed-9755491
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97554912022-12-17 Case report: Successful treatment with the combined therapy of interferon-alpha 2b and anlotinib in a patient with advanced hepatic epithelioid hemangioendothelioma Liu, Xiaolei Zhou, Ruiquan Si, Shuang Liu, Liguo Yang, Shiwei Han, Dongdong Tan, Haidong Front Med (Lausanne) Medicine Hepatic epithelioid hemangioendothelioma (HEH) is a very rare tumor originating from vascular endothelial cells, with unpredictable malignancy. At present, there is no standard treatment protocol yet established. Both surgical resection and liver transplantation have been reported to be effective treatments for HEH; however, multiple intrahepatic lesions or extrahepatic metastasis make these procedures unsuitable to most patients. Systematic therapy has also been investigated, but the results are undetermined due to the limited cases. Interferon-alpha 2b (IFN-a 2b) has also been used for the treatment of HEH. Based on our previous study, the rate of tumor regression with IFN-a 2b monotherapy was more than 50%. Here, we reported a patient with advanced HEH, who achieved a partial response with the combined therapy of anlotinib and IFN-a 2b. The tumor stayed stable for 2 years with anlotinib monotherapy and regressed 3 months after the combined therapy of anlotinib and IFN-a 2b. The synergistic effect of combined therapy with anlotinib and IFN-a 2b provided promising guidance for future clinical study. Frontiers Media S.A. 2022-12-02 /pmc/articles/PMC9755491/ /pubmed/36530920 http://dx.doi.org/10.3389/fmed.2022.1022017 Text en Copyright © 2022 Liu, Zhou, Si, Liu, Yang, Han and Tan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Liu, Xiaolei
Zhou, Ruiquan
Si, Shuang
Liu, Liguo
Yang, Shiwei
Han, Dongdong
Tan, Haidong
Case report: Successful treatment with the combined therapy of interferon-alpha 2b and anlotinib in a patient with advanced hepatic epithelioid hemangioendothelioma
title Case report: Successful treatment with the combined therapy of interferon-alpha 2b and anlotinib in a patient with advanced hepatic epithelioid hemangioendothelioma
title_full Case report: Successful treatment with the combined therapy of interferon-alpha 2b and anlotinib in a patient with advanced hepatic epithelioid hemangioendothelioma
title_fullStr Case report: Successful treatment with the combined therapy of interferon-alpha 2b and anlotinib in a patient with advanced hepatic epithelioid hemangioendothelioma
title_full_unstemmed Case report: Successful treatment with the combined therapy of interferon-alpha 2b and anlotinib in a patient with advanced hepatic epithelioid hemangioendothelioma
title_short Case report: Successful treatment with the combined therapy of interferon-alpha 2b and anlotinib in a patient with advanced hepatic epithelioid hemangioendothelioma
title_sort case report: successful treatment with the combined therapy of interferon-alpha 2b and anlotinib in a patient with advanced hepatic epithelioid hemangioendothelioma
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755491/
https://www.ncbi.nlm.nih.gov/pubmed/36530920
http://dx.doi.org/10.3389/fmed.2022.1022017
work_keys_str_mv AT liuxiaolei casereportsuccessfultreatmentwiththecombinedtherapyofinterferonalpha2bandanlotinibinapatientwithadvancedhepaticepithelioidhemangioendothelioma
AT zhouruiquan casereportsuccessfultreatmentwiththecombinedtherapyofinterferonalpha2bandanlotinibinapatientwithadvancedhepaticepithelioidhemangioendothelioma
AT sishuang casereportsuccessfultreatmentwiththecombinedtherapyofinterferonalpha2bandanlotinibinapatientwithadvancedhepaticepithelioidhemangioendothelioma
AT liuliguo casereportsuccessfultreatmentwiththecombinedtherapyofinterferonalpha2bandanlotinibinapatientwithadvancedhepaticepithelioidhemangioendothelioma
AT yangshiwei casereportsuccessfultreatmentwiththecombinedtherapyofinterferonalpha2bandanlotinibinapatientwithadvancedhepaticepithelioidhemangioendothelioma
AT handongdong casereportsuccessfultreatmentwiththecombinedtherapyofinterferonalpha2bandanlotinibinapatientwithadvancedhepaticepithelioidhemangioendothelioma
AT tanhaidong casereportsuccessfultreatmentwiththecombinedtherapyofinterferonalpha2bandanlotinibinapatientwithadvancedhepaticepithelioidhemangioendothelioma